Published in Exp Ther Med on May 30, 2012
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res (2010) 4.44
Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer (2011) 4.08
Assembly and function of DNA double-strand break repair foci in mammalian cells. DNA Repair (Amst) (2010) 2.51
Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways. Mutat Res (2011) 2.37
Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2005) 2.35
Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol (2010) 2.15
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta (2010) 1.77
Tip60: connecting chromatin to DNA damage signaling. Cell Cycle (2010) 1.73
A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation. DNA Repair (Amst) (2010) 1.71
Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol (2003) 1.69
Chromatin dynamics and the repair of DNA double strand breaks. Cell Cycle (2011) 1.63
gamma-H2AX as protein biomarker for radiation exposure. Ann Ist Super Sanita (2009) 1.57
PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol (2010) 1.55
Recent advances in radiotherapy. BMC Med (2010) 1.43
The micronucleus assay as a biological dosimeter of in vivo ionising radiation exposure. Mutagenesis (2011) 1.40
Radiation-induced alterations in cytokine production by skin cells. Exp Hematol (2007) 1.39
Delayed repair of radiation induced clustered DNA damage: friend or foe? Mutat Res (2010) 1.36
Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol (2011) 1.35
DNA damage and autophagy. Mutat Res (2011) 1.34
Adaptive radiotherapy of head and neck cancer. Semin Radiat Oncol (2010) 1.31
Clinical study of the necessity of replanning before the 25th fraction during the course of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2010) 1.25
The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control (2008) 1.23
Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol (2010) 1.22
The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol (2010) 1.21
Dose to normal tissues outside the radiation therapy patient's treated volume: a review of different radiation therapy techniques. Health Phys (2008) 1.19
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer (2010) 1.16
Emerging role of radiation induced bystander effects: Cell communications and carcinogenesis. Genome Integr (2010) 1.13
The promise of dynamic contrast-enhanced imaging in radiation therapy. Semin Radiat Oncol (2011) 1.12
Review of image-guided radiation therapy. Expert Rev Anticancer Ther (2007) 1.09
Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin Radiat Oncol (2010) 1.05
Physical radiotherapy treatment planning based on functional PET/CT data. Radiother Oncol (2010) 1.05
Targeting hypoxic cells through the DNA damage response. Clin Cancer Res (2010) 1.04
Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Semin Radiat Oncol (2010) 1.03
Tumor control probability in radiation treatment. Med Phys (2011) 1.03
Anatomic and dosimetric changes during the treatment course of intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma. Med Dosim (2009) 1.00
Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1. Biochem Pharmacol (2011) 0.99
The physical basis and future of radiation therapy. Br J Radiol (2011) 0.99
Low dose radiation response curves, networks and pathways in human lymphoblastoid cells exposed from 1 to 10cGy of acute gamma radiation. Mutat Res (2011) 0.97
Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther (2009) 0.96
Diffusion-weighted MRI for assessment of early cancer treatment response. Curr Pharm Biotechnol (2010) 0.94
Radiobiology goes 3D: how ECM and cell morphology impact on cell survival after irradiation. Radiother Oncol (2011) 0.94
A review of image-guided radiotherapy. Radiol Phys Technol (2008) 0.93
DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol (2010) 0.93
Tumor biology-guided radiotherapy treatment planning: gross tumor volume versus functional tumor volume. Semin Nucl Med (2008) 0.92
Molecular markers of radiation-related normal tissue toxicity. Cancer Metastasis Rev (2008) 0.91
Involvement of DNA-PK and ATM in radiation- and heat-induced DNA damage recognition and apoptotic cell death. J Radiat Res (2010) 0.90
Coordination of DNA-PK activation and nuclease processing of DNA termini in NHEJ. Antioxid Redox Signal (2010) 0.90
Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys (2009) 0.89
Multimodality molecular imaging of apoptosis in oncology. AJR Am J Roentgenol (2011) 0.87
Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents. Br Med Bull (2011) 0.86
[Determinants and predictive factors of tumour radiosensitivity]. Cancer Radiother (2008) 0.84
Regulation of stress-activated MAP kinase pathways during cell fate decisions. Nagoya J Med Sci (2011) 0.83
Double-strand breaks and the concept of short- and long-term epigenetic memory. Chromosoma (2010) 0.82
Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. Expert Opin Ther Pat (2009) 0.82
Clinical applications in molecular imaging. Pediatr Radiol (2010) 0.80
Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation. Future Oncol (2010) 0.80
Gating and tracking, 4D in thoracic tumours. Cancer Radiother (2010) 0.80
Image guidance and the new practice of radiotherapy: what to know and use from a decade of investigation. Front Radiat Ther Oncol (2011) 0.77
Advances in imaging: target delineation. Cancer J (2011) 0.77
The effect of significant tumor reduction on the dose distribution in intensity modulated radiation therapy for head-and-neck cancer: a case study. Med Dosim (2008) 0.76
Functional target volume delineation for radiation therapy on the basis of positron emission tomography and the correlation with histopathology. Q J Nucl Med Mol Imaging (2010) 0.76
Tumor volume is an independent prognostic indicator of local control in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Radiat Oncol (2013) 0.95
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy. Radiat Oncol (2014) 0.80
Graded-index optical fiber tweezers with long manipulation length. Opt Express (2014) 0.79
Optimization strategies for pulsed low-dose-rate IMRT of recurrent lung and head and neck cancers. J Appl Clin Med Phys (2014) 0.77
GSTP1 Ile105Val polymorphism and colorectal cancer risk: an updated analysis. Gene (2013) 0.76
Prognostic value of pretreatment 18F-FDG PET-CT for nasopharyngeal carcinoma patients. Medicine (Baltimore) (2017) 0.75
Treatment optimization with concurrent SBRT and intracavitary brachytherapy for locally advanced cervical cancer. J Appl Clin Med Phys (2016) 0.75
[Hydroxycamptothecin-based chemotherapy combined with concurrent radiotherapy for advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi (2004) 0.75